Following this activity, participants should be able to: (1) Summarize the clinical evidence that prompted the changes in indications of the PARP inhibitors, and compare and contrast the place in therapy of each. (2) Discuss key patient counseling points for both the PARP inhibitors, and mirvetuximab soravtansine-gynx. (3) Apply best practices for monitoring for and managing the drug-related toxicities of mirvetuximab soravtansine-gynx.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95313
- Start Date: 2024-06-04 05:00:00
- End Date: 2024-06-04 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest